California’s $8.4 billion research bond redraws the scale of immunology funding
California voters have approved $8.4 billion for immunology research, creating the largest infusion of science funding ever authorized by a public vote in the United States. The measure, known as Proposition 38, places the state at the center of a policy experiment with direct clinical consequences: whether a publicly financed research engine can accelerate therapies for cancer, Alzheimer’s disease, and other conditions shaped by immune dysfunction.
The size of the vote matters because it arrives at a moment when biomedical research in the state has been under pressure from political turbulence and federal funding cuts. California will pay for the program by issuing state government bonds, a financing approach usually reserved for roads, buildings, and other infrastructure. Here, the infrastructure is intellectual and biological rather than concrete — grants, laboratories, and translational pipelines designed to move immune-based discoveries toward treatment.
The proposition’s backers frame the money as a shield against instability. Antoni Ribas, a cancer researcher and physician at the University of California, Los Angeles, described the funding as “an advantage to California that is unprecedented,” arguing that it will strengthen the state’s position as a global hub for immunology research. The logic is straightforward. Immune-based medicine now sits at the center of oncology, vaccine development, and multiple chronic diseases, and those areas depend on sustained investment long before a drug reaches a clinic.
A single sentence captures the policy shift: California has chosen to finance biomedical discovery on a scale usually reserved for physical infrastructure.
The proposal ties public money to immune-based treatment development
The measure is not a generic science grant program. It is specifically aimed at research that seeks to find treatments capable of harnessing or re-engineering the body’s immune system, with explicit reference to illnesses such as cancer and Alzheimer’s disease. That focus reflects where modern immunology has already changed care and where the next gains are most likely to come from. Personalized cellular therapies, including CAR-T therapies, have already altered the treatment landscape for some cancers, while vaccine science continues to evolve through platforms such as mRNA.
Around $4 billion of the total will be distributed as competitive grants to researchers at selected public universities and non-profit institutes in California. The remaining funds are tied to a structure that has drawn scrutiny because about half of the money is earmarked directly for research institutes, and the criteria appear to fit a single institute co-founded by billionaire medical-device inventor Gary Michelson. Michelson drafted the proposition and contributed roughly $45 million of his own money to help place it on the ballot and support the campaign.
The royalty provisions also make the proposal unusually specific. Any commercialized therapies arising from the funded research must be sold at a 20% discount to people in California, and 10% of drug royalties would flow back into the state’s general fund. Those terms seek to convert public investment into public benefit, but they also raise questions about how tightly political design can be fused to biomedical translation.
A familiar California model, but at a larger and more controversial scale
California has used voter-approved science funding before. In 2004, after federal restrictions on human embryonic stem-cell research, voters approved a $3 billion bond to create the California Institute for Regenerative Medicine. The state later replenished that fund with another $5.5 billion in 2020. The new measure builds on that precedent, but the scale is larger and the target is different. Immunology has become one of the most commercially and clinically active areas in medicine, which makes the bet more immediate and also more contested.
The political logic behind the bond is easy to see. Federal support for biomedical research has been shaken by deep cuts, shifting oversight, and pressure placed on universities that depend on federal funding streams. In that environment, a state-level system can act as a stabilizer, preserving long-range projects that often collapse when grants are interrupted. For cancer immunology alone, a sustained pipeline matters because laboratory work, early translational studies, and clinical testing rarely fit neatly within a single federal budget cycle.
At the bedside, the promise is less abstract than the politics. Immune-based treatment strategies are already changing how some cancers are treated, and they continue to drive vaccine design and broader work on inflammatory disease biology. Investment at this level can support the preclinical work that determines whether a target is druggable, whether a biomarker is valid, and whether a therapy can move into human testing with a plausible safety profile.
The criticism centers on who benefits and how the money is routed
The proposal has also triggered skepticism. Sarah Hill, a political scientist at California State University, Fullerton, said she felt voters had been taken advantage of, reflecting concern that the structure appears to direct substantial resources toward a narrowly defined set of recipients. Michelson has said elsewhere that he will not personally profit from the bond revenue, but the criticism has persisted because the financial architecture is unusually concentrated for a public ballot measure.
This is where the scientific promise and the governance problem collide. Public financing can de-risk early research, but it also raises hard questions about transparency, recipient selection, and the boundary between civic philanthropy and private influence. When a measure of this size points toward a small set of institutes, the issue is not simply whether the science is worthy. The issue is whether the selection process is broad enough to justify the public debt attached to it.
Still, the vote is a clear signal that California intends to treat biomedical research as a strategic asset. The state has now linked debt financing to the possibility of new immune therapies, new vaccines, and new translational programs that could reach patients years from now. The outcome will depend on how competitively the grants are awarded, how much of the money actually reaches the laboratory bench, and whether the promised therapies emerge quickly enough to justify the political and fiscal cost.